T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells-Reference-Cited by-同舟云学术

T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells

Published:2016-08-25 Issue:8 Volume:128 Page:1081-1092
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Azzaoui Imane¹,Uhel Fabrice²³⁴⁵,Rossille Delphine¹³⁴⁵,Pangault Celine¹³⁴⁵,Dulong Joelle¹³⁴⁵,Le Priol Jerome¹,Lamy Thierry³⁴⁵⁶,Houot Roch³⁴⁵⁶,Le Gouill Steven⁷,Cartron Guillaume⁸,Godmer Pascal⁹,Bouabdallah Krimo¹⁰,Milpied Noel¹⁰,Damaj Gandhi¹¹^ORCID,Tarte Karin¹³⁴⁵^ORCID,Fest Thierry¹³⁴⁵,Roussel Mikael¹³⁴⁵^ORCID

Affiliation:

1. Pôle Biologie and

2. Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Rennes, France;

3. INSERM, Unité Mixte de Recherche U917, Equipe Labellisée Ligue Contre le Cancer, Rennes, France;

4. Université Rennes 1, Unité Mixte de Recherche U917, Rennes, France;

5. Etablissement Français du Sang Bretagne, Rennes, France;

6. Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France;

7. Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Nantes, Unité Mixte de Recherche 892 équipe 10, Nantes, France;

8. Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Montpellier, Montpellier, France;

9. Unité d'Hématologie Clinique, Centre Hospitalier de Bretagne Atlantique, Vannes, France;

10. Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; and

11. Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Caen, Caen, France

Abstract

Key Points Expansion of circulating monocytic myeloid-derived suppressor cells (MDSCs) correlates with clinical outcomes in patients with DLBCL. Mechanisms of MDSC-dependent T-cell inhibition in DLBCL are related to IL-10, PD-L1, and S100A12.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/8/1081/1465166/1081.pdf

Reference61 articles.

1. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.;Vaidya;Ann Oncol,2014

2. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project.;N Engl J Med,1993

3. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.;Sehn;Blood,2015

4. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.;Zhou;Blood,2014

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. S100A8 is a prognostic signature and associated with immune response in diffuse large B-cell lymphoma;Frontiers in Oncology;2024-02-01

2. Immune cells in the B-cell lymphoma microenvironment: From basic research to clinical applications;Chinese Medical Journal;2024-01-25

3. Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy;JAMA Oncology;2024-01-01

4. Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma;Frontiers in Immunology;2023-12-12

5. Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells;Journal of Hepatology;2023-12